Evidence map›Paper›PMID 30689565›Full record

ArticleJournal of Alzheimer's disease : JAD2019

Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.

Jack T Wiedrick, Jay I Phillips, Theresa A Lusardi, Trevor J McFarland, Babett Lind, Ursula S Sandau, Christina A Harrington, Jodi A Lapidus, Douglas R Galasko, Joseph F Quinn and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jack T WiedrickBiostatistics & Design Program, Oregon Health & Science University, Portland, OR, USA.
Jay I PhillipsDepartment of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.
Theresa A LusardiCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Trevor J McFarlandIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR, USA.
Babett LindDepartment of Neurology, Layton Aging and Alzheimer's Center, Oregon Health & Science University, Portland, OR, USA.
Ursula S SandauDepartment of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.
Christina A HarringtonIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR, USA.
Jodi A LapidusBiostatistics & Design Program, Oregon Health & Science University, Portland, OR, USA.
Douglas R GalaskoDepartment of Neurosciences, University of California, San Diego, CA, USA.
Joseph F QuinnDepartment of Neurology, Layton Aging and Alzheimer's Center, Oregon Health & Science University, Portland, OR, USA.
Julie A SaugstadDepartment of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.
Oregon Health & Science University · USIgenbio (United States) · USPortland VA Medical Center · USUniversity of California, San Diego · US

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Steven Dyal Edland · 2019 to 2026
$34.9M
Outreach, Recruitment and Education CoreP30AG008017 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI DODGE, HIROKO HAYAMA · 1990 to 2019
$27.7M
Optimization and Normalization Studies for Individual CSF SamplesUH3TR000903 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI QUINN, JOSEPH F, SAUGSTAD, JULIE ANNE · 2015 to 2016
$1.2M
Optimization and Normalization Studies for CSF as a BiomarkerUH2TR000903 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI QUINN, JOSEPH F, SAUGSTAD, JULIE ANNE · 2013 to 2014
$793k
NCATS NIH HHS UH2 TR000903NCATS NIH HHS UH3 TR000903NCATS NIH HHS UL1 TR002369NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG062429NIA NIH HHS P50 AG005131
6 · The paper itself

Abstract

We previously discovered microRNAs (miRNAs) in cerebrospinal fluid (CSF) that differentiate Alzheimer's disease (AD) patients from Controls. Here we examined the performance of 37 candidate AD miRNA biomarkers in a new and independent cohort of CSF from 47 AD patients and 71 Controls on custom TaqMan arrays. We employed a consensus ranking approach to provide an overall priority score for each miRNA, then used multimarker models to assess the relative contributions of the top-ranking miRNAs to differentiate AD from Controls. We assessed classification performance of the top-ranking miRNAs when combined with apolipoprotein E4 (APOE4) genotype status or CSF amyloid-β42 (Aβ42):total tau (T-tau) measures. We also assessed whether miRNAs that ranked higher as AD markers correlate with Mini-Mental State Examination (MMSE) scores. We show that of 37 miRNAs brought forth from the discovery study, 26 miRNAs remained viable as candidate biomarkers for AD in the validation study. We found that combinations of 6-7 miRNAs work better to identify AD than subsets of fewer miRNAs. Of 26 miRNAs that contribute most to the multimarker models, 14 have higher potential than the others to predict AD. Addition of these 14 miRNAs to APOE4 status or CSF Aβ42:T-tau measures significantly improved classification performance for AD. We further show that individual miRNAs that ranked higher as AD markers correlate more strongly with changes in MMSE scores. Our studies validate that a set of CSF miRNAs serve as biomarkers for AD, and support their advancement toward development as biomarkers in the clinical setting.

Indexed as

AgedAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4BiomarkersCase-Control StudiesFemaleGenotypeHumansMaleMicroRNAsPeptide FragmentsReal-Time Polymerase Chain ReactionReproducibility of Resultstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoprotein E4BiomarkersMAPT protein, humanMicroRNAsPeptide Fragmentstau ProteinsAlzheimer’s diseaseamyloid-β42apolipoprotein Ebiomarkerscerebrospinal fluidmicroRNAMini-Mental State Examinationtotal tau

Identifiers

PMID30689565
PMCPMC6687305
OpenAlexW2911681407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.